Perspective Therapeutics, Inc. (CATX)
(Delayed Data from AMEX)
$3.19 USD
-0.10 (-3.04%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $3.20 +0.01 (0.31%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CATX 3.19 -0.10(-3.04%)
Will CATX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CATX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CATX
Durect (DRRX) Reports Q2 Loss, Tops Revenue Estimates
electroCore, Inc. (ECOR) Reports Q2 Loss, Tops Revenue Estimates
CATX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amneal Pharmaceuticals (AMRX) Q2 Earnings Top Estimates
Journey Medical (DERM) Moves 16.8% Higher: Will This Strength Last?
Down -16.6% in 4 Weeks, Here's Why Perspective Therapeutics (CATX) Looks Ripe for a Turnaround
Other News for CATX
CATX forms 200 Day Moving Average Support on September 19
CATX Crossed Above 200 Day Moving Average on September 19
CATX: HC Wainwright & Co. Reiterates Buy Rating on Perspective Therapeutics | CATX Stock News
Optimistic Buy Rating for Perspective Therapeutics Driven by Promising Trial Results and Upcoming Catalysts
CATX Fell Below 200 Day Moving Average on September 17